Clinical Trials
9 trialsNCT05589896 2026-02-24
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Ossium Health, Inc.
Phase 1/2 Recruiting
NCT02206425 2023-10-31
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
Oncotherapeutics
Phase 1/2 Completed
NCT02756728 2020-03-12
A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma
BioInvent International AB
Phase 1/2 Terminated
NCT02614560 2019-01-09
A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients
Seagen Inc.
Phase 1/2 Terminated
NCT01335685 2018-01-23
Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma
Takeda
Phase 1/2 Completed
NCT02072863 2017-05-02
A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma
Amgen
Phase 1/2 Completed
NCT00743288 2014-05-08
Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma
Oncotherapeutics
Phase 1/2 Completed
NCT01983761 2013-11-18
Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation
Targazyme, Inc.
Phase 1/2 Unknown
NCT00421811 2010-12-28
A Study of ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan
Adherex Technologies, Inc.
Phase 1/2 Completed